On October 15, 2020 Savran Technologies Inc., a Massachusetts based biotech company with a mission to revolutionize non-invasive diagnostics via isolation of ultra-rare cells from blood, reported the completion of an important Phase 2 multi-center clinical trial conducted at 20 sites across the country utilizing its unique detection platform (Press release, Savran Technologies, OCT 15, 2020, View Source [SID1234568533]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The trial involved about 200 patients with early stage triple negative breast cancer who received chemotherapy and underwent surgery. An important goal of the study was to assess the utility of circulating markers (namely ctDNA and CTCs) in predicting whether the disease would relapse. The study, which is the largest of its kind to date, involved using circulating biomarkers with triple negative breast cancer who had residual disease. Results demonstrated that circulating markers were more successful in predicting relapse than other, more commonly used clinical markers such as tumor size, lymph node status, grade and stage. The study also showed that if a patient is negative for circulating markers, the chances of relapse are low. Augmenting a ctDNA analysis with Savran Technologies’ CTC analysis platform improved the sensitivity of predicting relapse to 90%.
"We are happy to see our technology help manage this agressive cancer," said Dr. Cagri Savran, the Founder and CEO of Savran Technologies Inc. "We expect our platform to be useful in a wide variety of conditions. Whole cells are precious biomarkers. They can be counted like in this clinical trial. They can be cultured to test drugs. They offer access to an intact genome which allows whole genome sequencing without a background. They can also complement other markers like ctDNA because we have seen instances where a patient was negative for ctDNA but positive for CTCs."
The application of Savran Technologies’s platform offers a unique benefit as seen in this landmark study in the field of cancer but also presents a meaningful opportunity in the prenatal field. "We are looking forward to exploring business development opportunities with innovative companies in these two fields of use who are interested in a technology platform offering a real competitive advantage" said Savran.